CPC-201 Phase 2 Results

Chase CPC-201 Presentation (June 2016) 


Publications related to the dose-response of acetylcholinesterase inhibitors.

Burns A, Rossor M, Hecker J, Gauthier S, Petit H, Möller HJ, Rogers SL, Friedhoff LT. The effects of donepezil in Alzheimer’s disease – results from a multinational trial. Dement Geriatr Cogn Disorder 1999; 10: 237-244.

Cummings J, Froelich L, Black SE, Bakchine S, Bellelli G, Molinuevo JL, Kressig RW, Downs P, Caputo A, Strohmaier. Randomized, double-blind, parallel group, 48-week study for efficacy and safety of a higher-dose rivastigmine patch (15 vs 10cm2) in Alzheimer Disease. Dement Geriatr Cogn Disorder 2012; 33:341-353.

Farlow MR, Salloway S, Tariot PN, Yardley J, Moline ML, Wang Q, Brand-Schieber E, Zou H, Hsu T, Satlin A. Effectiveness and tolerability of high-dose (23 mg/d) versus standard-dose (10 mg/d) donepezil in moderate to severe Alzheimer's disease: A 24-week, randomized, double-blind study. Clin Ther. 2010; 32:1234-51.

Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer’s disease. Donepezil Study Group. Neurology 1998; 50: 136-145.

Rupniak NM, Tye SJ, Field MJ. Enhanced performance of spatial and visual recognition memory tasks by the selective acetylcholinesterase inhibitor E2020 in rhesus monkeys. Psychopharmacology (Berl). 1997;131:406-10.

Winblad B, Cummings J, Andreasen N, Grossberg G, Onofrj M, Sadowsky C, Zechner S, Nagel J, Lane R. A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer's disease--rivastigmine patch versus capsule. Int J Geriatr Psychiatry. 2007; 22:456-67.

Winblad B, Grossberg G, Frölich L, Zechner S, Nagel J, Lane R. IDEAL: a 6-month, double-blind, placebo controlled study of the first skin patch for Alzheimer disease. Neurology 2007; 69:S14-22.